Back to Peptide Library
Anti-Inflammatory Tripeptide

KPV

Lys-Pro-Val • C-Terminal α-MSH Fragment

KPV is a three-amino-acid fragment of alpha-MSH investigated for intestinal and broader inflammatory signaling. Oral mouse-colitis studies and cellular work are promising, while human treatment studies remain absent.

Routes
Oral capsule, SubQ
Compound type
Tripeptide
Regulatory status
Not FDA approved
Last reviewed
At a glance

KPV Quick Reference

SubQ range
200–400mcg
Community once-daily use
Oral range
200–500mcg
Community once or twice daily
Cycle
4–8 weeks
Community convention, not a trial-tested course
Research focus
Gut inflammation
PepT1-mediated uptake in mouse models
Overview

What Is KPV?

KPV is the lysine-proline-valine sequence at the C-terminal end of alpha-melanocyte-stimulating hormone (alpha-MSH). Researchers isolated it because the short fragment retains anti-inflammatory activity in experimental systems without reproducing the parent hormone’s strong pigment effects.

Its small tripeptide structure makes oral delivery an interesting research route. The intestinal peptide transporter PepT1 can move KPV into epithelial and immune cells. PepT1 is normally prominent in the small intestine and can rise in inflamed colonic tissue; oral KPV reduced inflammation in two mouse-colitis models.

Laboratory studies also explored NF-κB and MAPK signaling, antimicrobial activity, and local delivery to skin or mucosal tissue. These findings support the research rationale but do not establish that an oral capsule or SubQ injection treats inflammatory disease in humans.

Mechanism

KPV Mechanism of Action

Alpha-MSH fragment

KPV is the terminal three-amino-acid sequence of alpha-MSH, retaining anti-inflammatory activity in experimental models.

PepT1 uptake

The intestinal di- and tripeptide transporter PepT1 carries KPV into epithelial and immune cells in the gut.

Inflammatory signaling

In cell and mouse studies, KPV reduced NF-κB, MAPK, and downstream inflammatory cytokine signaling.

Clinical translation

These mechanisms do not establish human oral bioavailability, therapeutic dose, or benefit from SubQ use.

Research findings

KPV Benefits

Disease-related findings remain preclinical; human treatment outcomes are not established.

Gut Inflammation Models

Oral KPV reduced disease severity and inflammatory markers in DSS- and TNBS-induced mouse colitis.

Immune Modulation

Cell experiments show less NF-κB and MAPK signaling after PepT1-mediated KPV uptake.

Antimicrobial Activity

Alpha-MSH C-terminal peptides showed direct laboratory activity against selected bacteria and fungi.

Skin & Mucosal Research

Local anti-inflammatory effects have been explored in tissue models, but psoriasis, eczema, and wound-healing claims remain unproven in people.

Barrier Research

Experimental delivery systems improved tight-junction and mucosal-healing markers in colitis models.

Colitis-Associated Cancer Models

A mouse study found lower colitis-associated tumor development with PepT1-mediated KPV treatment; it does not establish cancer prevention in humans.

Protocol planning

KPV Dosing Protocol

KPV is discussed as an oral capsule for gut-focused research and as a SubQ injection for broader systemic use. These community ranges are route-specific; no human trial establishes an effective dose or schedule.

Members Access Only

Sign in or create a free account to view this content.

Preparation

KPV Reconstitution

Example concentration

10mg vial + 2mL bacteriostatic water

Result5mg/mL

Reconstitution steps

1
Prepare

Wash your hands, clean the work surface, and wipe both vial stoppers with alcohol. Allow them to dry.

2
Add diluent slowly

Use a new sterile syringe and needle to direct the selected volume of compatible diluent down the inside wall of the vial.

3
Dissolve gently

Swirl or roll the vial until the contents dissolve; do not shake.

4
Store

Store refrigerated at 2–8°C (36–46°F) and protected from light when the product instructions support this. Record the reconstitution date in your research journal.

N=1 reports

KPV Community Experience

Positive Reports

  • Oral users often describe less gut irritation or improved comfort over several weeks.
  • Some report calmer systemic inflammatory symptoms with SubQ use.
  • KPV is frequently discussed alongside BPC-157 in gut-focused capsule protocols.

Negative & Mixed Reports

  • Some users notice little or no clear change.
  • Injection-site irritation and mild GI upset appear in anecdotal reports.
  • Different forms, doses, and co-administered products make attribution difficult.
Stacking & synergy

KPV Stacking & Synergy

These pairings are based on community experience and distinct research targets, not controlled combination trials.

KPV + BPC-157

Our preferred oral gut pairing. KPV targets inflammatory signaling in mouse colitis models; BPC-157 is studied in mucosal injury and repair. The capsule combination has worked well in our experience.

KPV + KLOW

KPV is one component of KLOW. A blend can be convenient, though it makes individual contribution harder to judge.

KPV + GHK-Cu

A community pairing across inflammation and tissue-remodeling research, particularly for skin interest. Added benefit is unproven.

KPV + GLP-1 Agonists

Some users discuss KPV for gut comfort alongside appetite-focused drugs, but no controlled study shows that it offsets GI adverse effects.

Safety notes

KPV Side Effects & Safety

KPV has no established human therapeutic dose, approved route, or reliable adverse-event rate. Animal and cell findings do not define long-term human safety.

Community Reports

  • Injection-site redness or discomfort with SubQ use.
  • Occasional nausea, GI upset, or headache.
  • Oral product quality and tolerability vary.

Unresolved Risks

  • Long-term immune and metabolic effects remain unknown.
  • Injectable quality, sterility, and contamination are material concerns.
  • Preclinical tumor findings in colitis models do not establish human cancer safety or prevention.

KPV Precautions

Avoid or Discuss With a Clinician If
  • Known hypersensitivity to KPV or a formulation ingredient.
  • Pregnancy or breastfeeding, where safety data are absent.
  • Active serious inflammatory disease or cancer requiring established medical care.
Use Caution With
  • Other medications or compounds that make adverse effects difficult to attribute.
  • Unverified oral products or injectable vial quality.
  • Assumptions that oral capsule and SubQ amounts are interchangeable.
KPV is not FDA approved for any human therapeutic indication.
Final verdict

Peptide Protocols Verdict on KPV

Not medical advice. This editorial is our own opinion piece based off the experience of our own lab rats.
Our opinionated opinion

KPV is one of our favorite gut-focused peptides. In capsule form with BPC-157, it has made a clear difference in our own gut comfort. We cannot separate which peptide did how much, but the pairing is one we would pay attention to again.

We also like how focused KPV’s research story is: a tiny alpha-MSH fragment, PepT1 transport, and repeatable anti-inflammatory findings in gut models. We would not present that as proof of treating IBD or systemic inflammation in people, and we do not assume oral and SubQ use produce the same result. Our positive experience and the preclinical rationale earn it a B; the lack of controlled human evidence keeps it there.